ID

13711

Descripción

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01466790

Link

https://clinicaltrials.gov/show/NCT01466790

Palabras clave

Versiones (1)
  1. 29/2/16 29/2/16 -
Subido en

29 de febrero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Hepatitis C NCT01466790

Inglés

Eligibility Hepatitis C NCT01466790

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
chronic genotype 1 hepatitis c virus (hcv) infection
Descripción

chronic hepatitis c

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0524910
plasma hcv rna of more than 10,000 iu/ml at screening
Descripción

plasma hepatitis c virus rna

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1977893
patients in cohort 1 must be null responders to pegifn/ribavirin with at least 1 documented previous course of pegifn/ribavirin therapy for at least 12 consecutive weeks
Descripción

therapy ribavirin; therapy response for hepatitis c virus infection

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0035525
UMLS CUI [2]
C2750389
patients in cohort 2 must be null responders to pegifn/ribavirin with at least 1 documented previous course of pegifn/ribavirin therapy for at least 12 consecutive weeks and could also be hcv treatment-naive, meaning never received treatment with any approved or investigational drug for the treatment of hcv
Descripción

therapy response for hepatitis c virus infection; Therapy naive Hepatitis C

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2750389
UMLS CUI [2,1]
C0919936
UMLS CUI [2,2]
C0019196
null responders patients in cohort 1 and cohort 2 must meet the defined criterion for a null responder, defined as on-treatment less than 2 log10 iu/ml reduction in hcv rna from baseline at week 12 of the most recent pegifn/ribavirin therapy
Descripción

hepatitis c virus; cohort; no response to treatment

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220847
UMLS CUI [2]
C0599755
UMLS CUI [3]
C0184782
patient must have had a liver biopsy within 3 years before screening (or between screening and baseline visit) or patient must have had a liver biopsy at any time in the past which showed metavir f3 or f4 fibrosis
Descripción

liver biopsy; screening; metavir fibrosis score

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0193388
UMLS CUI [2]
C0220908
UMLS CUI [3]
C3897040
must agree to use 2 forms of effective contraception throughout the study (male and female)
Descripción

contraception

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0700589
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
has evidence of hepatic decompensation
Descripción

hepatic decompensation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0085605
has any liver disease of non-hcv etiology
Descripción

liver disease; etiology

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023895
UMLS CUI [2]
C1314792
has an infection/co-infection with non-genotype 1 hcv
Descripción

HCV coinfection; hcv genotype

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1698259
UMLS CUI [2]
C1148363
has a co-infection with human immunodeficiency virus (hiv) type 1 or type 2 (hiv-1 or hiv-2) (positive hiv-1 or hiv-2 antibody test at screening)
Descripción

coinfection hiv; hiv antibody test

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0019682
UMLS CUI [1,2]
C0275524
UMLS CUI [2]
C2229753
has a co-infection with hepatitis b virus (hepatitis b surface antigen [hbsag] positive)
Descripción

HBV coinfection; Hepatitis B surface antigen positive

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2242656
UMLS CUI [2]
C0149709
has a history of malignancy within 5 years of the screening visit
Descripción

medical history malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0006826
Volver a la parte superior de la página

Similar models

Eligibility Hepatitis C NCT01466790

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
chronic hepatitis c
Item
chronic genotype 1 hepatitis c virus (hcv) infection
boolean
C0524910 (UMLS CUI [1])
plasma hepatitis c virus rna
Item
plasma hcv rna of more than 10,000 iu/ml at screening
boolean
C1977893 (UMLS CUI [1])
therapy ribavirin; therapy response for hepatitis c virus infection
Item
patients in cohort 1 must be null responders to pegifn/ribavirin with at least 1 documented previous course of pegifn/ribavirin therapy for at least 12 consecutive weeks
boolean
C0087111 (UMLS CUI [1,1])
C0035525 (UMLS CUI [1,2])
C2750389 (UMLS CUI [2])
therapy response for hepatitis c virus infection; Therapy naive Hepatitis C
Item
patients in cohort 2 must be null responders to pegifn/ribavirin with at least 1 documented previous course of pegifn/ribavirin therapy for at least 12 consecutive weeks and could also be hcv treatment-naive, meaning never received treatment with any approved or investigational drug for the treatment of hcv
boolean
C2750389 (UMLS CUI [1])
C0919936 (UMLS CUI [2,1])
C0019196 (UMLS CUI [2,2])
hepatitis c virus; cohort; no response to treatment
Item
null responders patients in cohort 1 and cohort 2 must meet the defined criterion for a null responder, defined as on-treatment less than 2 log10 iu/ml reduction in hcv rna from baseline at week 12 of the most recent pegifn/ribavirin therapy
boolean
C0220847 (UMLS CUI [1])
C0599755 (UMLS CUI [2])
C0184782 (UMLS CUI [3])
liver biopsy; screening; metavir fibrosis score
Item
patient must have had a liver biopsy within 3 years before screening (or between screening and baseline visit) or patient must have had a liver biopsy at any time in the past which showed metavir f3 or f4 fibrosis
boolean
C0193388 (UMLS CUI [1])
C0220908 (UMLS CUI [2])
C3897040 (UMLS CUI [3])
contraception
Item
must agree to use 2 forms of effective contraception throughout the study (male and female)
boolean
C0700589 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
hepatic decompensation
Item
has evidence of hepatic decompensation
boolean
C0085605 (UMLS CUI [1])
liver disease; etiology
Item
has any liver disease of non-hcv etiology
boolean
C0023895 (UMLS CUI [1])
C1314792 (UMLS CUI [2])
HCV coinfection; hcv genotype
Item
has an infection/co-infection with non-genotype 1 hcv
boolean
C1698259 (UMLS CUI [1])
C1148363 (UMLS CUI [2])
coinfection hiv; hiv antibody test
Item
has a co-infection with human immunodeficiency virus (hiv) type 1 or type 2 (hiv-1 or hiv-2) (positive hiv-1 or hiv-2 antibody test at screening)
boolean
C0019682 (UMLS CUI [1,1])
C0275524 (UMLS CUI [1,2])
C2229753 (UMLS CUI [2])
HBV coinfection; Hepatitis B surface antigen positive
Item
has a co-infection with hepatitis b virus (hepatitis b surface antigen [hbsag] positive)
boolean
C2242656 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
medical history malignancy
Item
has a history of malignancy within 5 years of the screening visit
boolean
C0262926 (UMLS CUI [1,1])
C0006826 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial